Amylyx Shares Jump 56% After Avexitide Succeeds in Phase 3 Hypoglycemia Trial
Amylyx Pharmaceuticals announced Tuesday that its investigational drug avexitide met both primary and secondary efficacy endpoints in a Phase 3 clinical trial for post-bariatric hypoglycemia. The therapy, a GLP-1 blocker, reduced dangerous low-blood-sugar events. Following the positive results, the company's stock surged 56% to $32.26.
Key facts
- Amylyx Pharmaceuticals reported results on Tuesday
- Avexitide met primary and secondary endpoints in a Phase 3 trial
- The trial targeted post-bariatric hypoglycemia
- Avexitide is a GLP-1 blocker
- The drug cut dangerous low-blood-sugar events
- Stock rose 56% to $32.26
Entities
Institutions
- Amylyx Pharmaceuticals
Sources
- Quartz —